Mitomycin, ifosfamide, and mesna in the treatment of lung cancer

Research output: Contribution to journalArticle

Abstract

Observations have been made of the multiple-drug resistance phenomenon in mitomycin-exposed cells in vitro. Collateral resistance to anthracyclines and Vinca alkaloids was demonstrated in mitomycin carbon-treated 1-1210 cells in vitro. However, because it has also been found that this resistance can be reversed with agents such as verapamil and progestogens, it may be possible to effect a similar reversal in vivo. A study is currently being performed in patients with colorectal cancer, in which the potential for reversal is being tested. The pharmacokinetics of ifosfamide result in high cytotoxic specificity which, along with its therapeutic range, makes it a particularly active agent in the treatment of non-small cell lung cancer. Its urotoxicity is effectively controlled by the coadministration of mesna, a uroprotective agent.

Original languageEnglish (US)
Pages (from-to)2-5
Number of pages4
JournalSeminars in Oncology
Volume17
Issue number4 SUPPL. 7
StatePublished - 1990

Fingerprint

Mesna
Ifosfamide
Mitomycin
Lung Neoplasms
Vinca Alkaloids
Anthracyclines
Multiple Drug Resistance
Progestins
Verapamil
Non-Small Cell Lung Carcinoma
Colorectal Neoplasms
Carbon
Pharmacokinetics
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology

Cite this

Mitomycin, ifosfamide, and mesna in the treatment of lung cancer. / Dorr, Robert T.

In: Seminars in Oncology, Vol. 17, No. 4 SUPPL. 7, 1990, p. 2-5.

Research output: Contribution to journalArticle

@article{a1a4030f6df24819823300763a4d647e,
title = "Mitomycin, ifosfamide, and mesna in the treatment of lung cancer",
abstract = "Observations have been made of the multiple-drug resistance phenomenon in mitomycin-exposed cells in vitro. Collateral resistance to anthracyclines and Vinca alkaloids was demonstrated in mitomycin carbon-treated 1-1210 cells in vitro. However, because it has also been found that this resistance can be reversed with agents such as verapamil and progestogens, it may be possible to effect a similar reversal in vivo. A study is currently being performed in patients with colorectal cancer, in which the potential for reversal is being tested. The pharmacokinetics of ifosfamide result in high cytotoxic specificity which, along with its therapeutic range, makes it a particularly active agent in the treatment of non-small cell lung cancer. Its urotoxicity is effectively controlled by the coadministration of mesna, a uroprotective agent.",
author = "Dorr, {Robert T}",
year = "1990",
language = "English (US)",
volume = "17",
pages = "2--5",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 7",

}

TY - JOUR

T1 - Mitomycin, ifosfamide, and mesna in the treatment of lung cancer

AU - Dorr, Robert T

PY - 1990

Y1 - 1990

N2 - Observations have been made of the multiple-drug resistance phenomenon in mitomycin-exposed cells in vitro. Collateral resistance to anthracyclines and Vinca alkaloids was demonstrated in mitomycin carbon-treated 1-1210 cells in vitro. However, because it has also been found that this resistance can be reversed with agents such as verapamil and progestogens, it may be possible to effect a similar reversal in vivo. A study is currently being performed in patients with colorectal cancer, in which the potential for reversal is being tested. The pharmacokinetics of ifosfamide result in high cytotoxic specificity which, along with its therapeutic range, makes it a particularly active agent in the treatment of non-small cell lung cancer. Its urotoxicity is effectively controlled by the coadministration of mesna, a uroprotective agent.

AB - Observations have been made of the multiple-drug resistance phenomenon in mitomycin-exposed cells in vitro. Collateral resistance to anthracyclines and Vinca alkaloids was demonstrated in mitomycin carbon-treated 1-1210 cells in vitro. However, because it has also been found that this resistance can be reversed with agents such as verapamil and progestogens, it may be possible to effect a similar reversal in vivo. A study is currently being performed in patients with colorectal cancer, in which the potential for reversal is being tested. The pharmacokinetics of ifosfamide result in high cytotoxic specificity which, along with its therapeutic range, makes it a particularly active agent in the treatment of non-small cell lung cancer. Its urotoxicity is effectively controlled by the coadministration of mesna, a uroprotective agent.

UR - http://www.scopus.com/inward/record.url?scp=0025164047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025164047&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 2

EP - 5

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 7

ER -